Please use this identifier to cite or link to this item:
Title: A ‘Disease Severity Index’ to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia
Austin Authors: Ferreira, Daniel;Falahati, Farshad;Linden, Cecilia;Buckley, Rachel F;Ellis, Kathryn A;Savage, Greg;Villemagne, Victor L ;Rowe, Christopher C ;Ames, David;Simmons, Andrew;Westman, Eric
Affiliation: Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
Melbourne School of Psychological Sciences, University of Melbourne, Parkville, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia
Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
The Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, Victoria, Australia
ARC Centre of Excellence in Cognition and its Disorders, Department of Psychology, Macquarie University, Sydney, NSW, Australia
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
NIHR Biomedical Research Centre for Mental Health, London, UK
NIHR Biomedical Research Unit for Dementia, London, UK
Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
Issue Date: 13-Mar-2017
Publication information: Scientific Reports 2017; 7: 44368
Abstract: Subjective memory decline (SMD) is a heterogeneous condition. While SMD might be the earliest sign of Alzheimer’s disease (AD), it also occurs in aging and various neurological, medical, and psychiatric conditions. Identifying those with higher risk to develop dementia is thus a major challenge. We tested a novel disease severity index generated by multivariate data analysis with numerous structural MRI measures as input. The index was used to identify SMD individuals with high risk of progression to mild cognitive impairment (MCI) or AD. A total of 69 healthy controls, 86 SMD, 45 MCI, and 38 AD patients were included. Subjects were followed up for 7.5 years. Clinical, cognitive, PET amyloid imaging and APOE ε4 data were used as outcome variables. The results showed that SMD evidenced cognitive performance intermediate between healthy controls and MCI. The disease severity index identified eleven (13%) SMD individuals with an AD-like pattern of brain atrophy. These individuals showed lower cognitive performance, increased CDR-SOB, higher amyloid burden and worse clinical progression (6.2 times higher likelihood to develop MCI, dementia or die than healthy controls). The current disease severity index may have relevance for clinical practice, as well as for selecting appropriate individuals for clinical trials.
DOI: 10.1038/srep44368
ORCID: 0000-0002-5356-5537
PubMed URL:
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 2, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.